To assess the effects of a-blockers compared to standard therapy or placebo for ureteric stones of ≤10 mm confirmed by imaging in adult patients presenting with symptoms of ureteric stone disease.
Patients and Methods
We performed a systematic search in multiple databases and grey literature with no restrictions on the language of publication or publication status, up until November 2017. We included randomised controlled trials evaluating ureteric stone passage in adult patients that compared a-blockers with standard therapy or placebo. Two review authors were independently responsible for study selection, data extraction, and risk-of-bias assessment. We performed a meta-analysis using a random-effect model. The quality of evidence was assessed on outcome basis according to Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.
Results
We included 67 studies, with 10 509 participants overall. Of these, 15 studies with 5 787 participants used a placebo. Stone clearance: treatment with an a-blocker may result in a large increase in stone clearance (risk ratio [RR] 1.45, 95% confidence interval [CI] 1.36-1.55; low-quality evidence), corresponding to 278 more (95% CI: 223-340 more) stone clearances per 1 000 participants. For major adverse events, treatment with an a-blocker may have little effect (RR 1.25, 95% CI: 0.80-1.96; low-quality evidence), which corresponds to five more (95% CI four fewer to 19 more) major adverse events per 1 000 participants. Patients treated with a-blockers may also experience shorter stone expulsion times (mean difference [MD] À3.40 days, 95% CI: À4.17 to À2.63; lowquality evidence), use less diclofenac (MD À82.41 mg, 95% CI: À122.51 to À42.31; low-quality evidence) and likely require fewer hospitalisations (RR 0.51, 95% CI: 0.34-0.77; moderate-quality evidence). Meanwhile, the need for surgical intervention appears similar (RR 0.74, 95% CI: 0.53-1.02; low-quality evidence). Based on a pre-defined subgroup analysis (test for subgroup difference, P = 0.002), there may be a different effect of a-blockers based on stone size with RRs of 1.06 (95% CI: 0.98-1.15; P = 0.16; I² = 62%) for stones of ≤5 mm vs 1.45 (95% CI: 1.22-1.72; P < 0.0001; I² = 59%) for stones of >5 mm. We did not find evidence for possible subgroup effects based on stone location or a-blocker type.
Introduction
Urinary stone disease refers to the formation of stones or calculi in the urinary tract and is one of the most common reasons for patients to visit a urology practice; affecting about 5-10% of the population [1] . An even higher frequency of up to 12% has been reported from other parts of the world, with only a few geographical areas in which stone disease is rare (e.g. in Greenland and in the coastal areas of Japan) [2] . A more recent study showed an increase in lifetime prevalence of stone disease from 7.14% to 11.62% over a 10-year period (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) [3]. The incidence and prevalence rates of kidney stones may be affected by genetic, nutritional, and environmental factors. Caucasian males are more likely to develop urinary stones compared with Asians, Hispanics, and African Americans [4] . Besides the probability of stone formation, stone composition and location in the urinary tract also differ between different countries [1] .
Furthermore, in the USA, >2 million outpatient visits for a primary diagnosis of urinary stones were recorded in 2000 [5] . Hospital outpatient visits increased by 40% between 1994 and 2000, and physician office visits increased by 43% between 1992 and 2000. In the USA, the total estimated annual cost for stone disease was >$10.3 billion (American dollars) in 2006, an almost five-fold increase in 6 years ($2.1 billion in 2000), representing a 50% increase since 1994. An even further increase was seen to >$3 billion of costs for emergency room visits in the USA in 2009 [6] . This rise could only in part be explained by the increasing prevalence of stone disease [4] .
The natural history of urinary stone disease is characterised by specific steps from the formation of Randall's plaques to stones that cause renal or ureteric colic [7] . Symptoms include flank or abdominal pain radiating to the groin or external genitalia. Although some patients with ureteric stones might remain asymptomatic, many have pain and generally seek medical care. An acute episode of colic is the result of a stone entering the ureter and causing an intermittent rise of pressure in the pyelocalyceal system. Spontaneous passage will occur in most of these stones. Stone size and location are the two most important predictors of stone passage [8] . Passage rates of 68% for stones of <5 mm and 47% for stones >5 mm and ≤10 mm have been reported [9] .
Medical expulsive therapy (MET) and in particular a-blockers may facilitate stone passage (European Association of Urology [EAU] guidelines on diagnosis and conservative management of urolithiasis 2016; AUA Guideline 2016 Surgical Management of Stones) [10] . There are several potential benefits. First, MET may decrease the duration of symptoms of ureteric stones and, therefore, the rate of complications such as UTIs, hydronephrosis, and kidney function impairment. Second, MET can potentially decrease the use of more invasive interventions, such as extracorporeal shockwave lithotripsy and ureteroscopy and, therefore, may decrease the rate of possible complications of these procedures. Last, MET is likely to spare limited healthcare resources, such as physician time and hospital beds.
Despite the joint guideline by the EAU and the AUA, considerable controversy still persists concerning the best treatment approach for ureteric stones and the effectiveness of a-blocker use as MET. Several randomised controlled trials (RCTs) have been published recently on this topic with conflicting conclusions. It is important to do an up-to-date systematic review with all the available data of recent RCTs using the highest methodological standards, as well as the application of the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach, to rate the quality of the evidence. In summary, combining the studies performed to date offers the opportunity to produce an overall effect estimate of ablockers as MET for ureteric stones. The direction and magnitude of this effect will help in guiding decisions about clinical practice.
This present Cochrane review concerns an update of the previous Cochrane review [10] . Since the date of the last search strategy (9 July 2012), several new studies have been published. This warrants the need to update this Cochrane review.
Patients and Methods

Search Strategy and Selection Criteria
We performed a systematic search in November 2017 using multiple database of the Cochrane Central Register of Controlled Trials in the Cochrane Library (CENTRAL), MEDLINE Ovid, MEDLINE In-Process and Other NonIndexed Citations, EMBASE Ovid, and PubMed (Appendix S1). Additionally, we hand-searched the conference proceedings from the EAU, AUA, Experts in Stone Disease, World Congress of Endourology, and Soci et e Internationale d'Urologie. Two review authors (T.C. and X.Z.) independently screened all potentially relevant records. We included all RCTs and quasi-RCTs (quasi-RCTs being trials in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth, or other predictable methods) investigating a-blockers for the treatment of ureteric stones in adult patients. We included studies regardless of their publication status or language of publication.
Types of Participants
Adult patients (aged ≥18 years), who presented with symptoms of ureteric stones, were included. The diagnosis of ureteric stones was confirmed by imaging (e.g. plain abdominal radiograph of the kidneys, ureters and bladder, CT, pyelography, or ultrasonography), and it concerned a single stone of ≤10 mm. Patients with evidence of UTI or hydronephrosis with complicated factors, kidney or ureteric abnormalities, pregnant or lactating women, bilateral stones, or patients taking an a-blocker, a calcium-channel blocker, or having allergies to these medication were excluded.
Types of Intervention
MET with a-blockers for treating ureteric stones were compared with: (i) standard therapy (e.g. NSAIDs, corticosteroids, antispasmodics) or (ii) placebo. When multiple a-blockers were compared in one study, the arms were combined in the comparison a-blockers vs standard therapy or placebo and the effect of different a-blockers was investigated in subgroup analyses. a-blockers adjuvant to surgery or lithotripsy were excluded. If patients used other medications, such as anticholinergics or antispasmodics, as adjuvant to the trial medication, we only evaluated comparable groups.
Types of Outcomes Measured
The primary outcomes of our present review were stone clearance and major adverse events. Secondary outcomes were stone expulsion time, pain episodes, diclofenac use, hospitalisation, and surgical intervention.
Assessment of Risk of Bias in Included Studies
Two review authors (T.C. and X.Z.) independently assessed the risk of bias of each included studies and disagreements were resolved by consensus or consultation with a third review author (T.L.). The risk of bias was assessed using the Cochrane Risk of Bias assessment tool and defined as 'low risk', 'high risk', or 'unclear risk' derived from the Cochrane Handbook [11] .
Data Collection and Data Extraction
Two review authors (T.C. and X.Z.) independently extracted the data of the aforementioned outcomes using a data extraction form. We attempted to retrieve the event rate and total sample size for dichotomous outcomes and means with standard deviations (SDs) for continuous outcomes. We performed our meta-analysis with a random-effects model and assessed heterogeneity statistically with I 2 statistics. The I 2 values of 0-40%, 30-60%, 50-90%, 75-100% were considered, respectively, 'not important', 'moderate heterogeneity', 'substantial heterogeneity', and 'considerable heterogeneity' [11] . If we included ≥10 studies on one outcome, we used funnel plots to assess small study effects. We used Review Manager 5 software to perform statistical analyses [12] .
Subgroup Analysis
We conducted three different subgroup analyses to explore possible sources of heterogeneity: (i) Stone size (stones ≤5 vs 6-10 mm), (ii) stone location (distal vs mid-or proximal ureteric stones), and (iii) type of a-blocker. Analyses were carried out as for our primary outcomes.
Summary of Findings Table
We presented the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account five criteria not only related to internal validity (risk of bias, inconsistency, imprecision, publication bias) but also to external validity such as directness of results [13] . 
Results
Search Results
We identified 127 references through a systematic search and no additional records were identified through other sources. Based on our criteria, 121 potentially relevant titles were identified and the full text of these articles was assessed (Appendices S2 and S3). The evidence selection is shown in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flowchart [14] (Fig. 1) .
Included Studies
In total, 67 studies were included in our review (Appendix S2). Most studies (52 of 67) compared a-blockers with standard therapy (i.e. NSAIDs, corticosteroids, or antispasmodics) [18, [20] [21] [22] [23] [24] [25] [26] [27] [28] 30, 31, 33, 34, [36] [37] [38] [39] [40] [42] [43] [44] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] 63, [66] [67] [68] [69] [70] [71] 73, 75, [77] [78] [79] [80] [81] , and the other studies (15 of 67) compared a-blockers with placebo [15] [16] [17] 19, 29, 32, 35, 41, 45, 62, 64, 65, 72, 74, 76] . The sample size varied from 30 to 3 440, the mean or median age varied from 32 to 56 years, and the duration of follow-up varied from 1 to 8 weeks.
Risk of Bias
The risk of bias is summarised in Figs 2 and 3.
Allocation (Selection Bias)
Of the 67 studies, 36 and 50 studies described methods of sequence generation and allocation, respectively, with an unclear risk of selection bias. In all, 26 and 15 studies had a low risk of bias, respectively. Five and two studies were judged as having a high risk of bias, respectively.
Blinding (Performance and Detection Bias)
In total, 48 and 56 studies were judged as having an unclear risk of performance and detection bias, respectively. In all, 14 and 10 studies had a low risk of bias, respectively. Five and one study, were judged as having a high risk of bias, respectively.
Incomplete Outcome Data (Attrition Bias)
In total, 47 studies were judged with a low risk of attrition bias. Whilst, 12 studies had an unclear risk of bias and eight had a high risk of bias.
Selective Reporting (Reporting Bias)
The funnel plot as shown in Fig. 4 was asymmetric. Of the 67 included studies, 42 studies were judged as having a low risk of reporting bias. Whilst, 12 studies had an unclear risk of bias and 13 had a high risk of bias. 
Outcome: Stone Clearance
Based on 67 RCTs with 10 509 participants, treatment with an a-blocker may result in a large increase in stone clearance (RR 1.45, 95% CI: 1.36-0.55; P < 0.001; I² = 76%, low-quality evidence due to study limitations, inconsistency and concerns about publication bias); this corresponds to 278 more (95% CI: 223-340 more) stone clearances per 1 000 participants.
Outcome: Major Adverse Events
Major adverse events were described in 18 studies with 3 124 participants. Treatment with an a-blocker may have little effect on major adverse events (RR 1.25, 95% CI: 0.80-1.96; P = 0.33; I² = 0%, low-quality evidence due to study limitations and imprecision); this corresponds to five more (95% CI four fewer to 19 more) major adverse events per 1 000 participants.
Outcome: Stone Expulsion Time
Stone expulsion time was described in 37 studies with 6 031 participants. Treatment with an a-blocker may reduce the time to stone passage substantially (mean difference [MD] À3.40 days, 95% CI: À4.17 to À2.63; P < 0.001; I² = 94%, low-quality evidence due to study limitations, inconsistency, and concerns about publication bias).
Outcome: Pain Episodes
The number of pain episodes was reported in 15 studies with 1 363 participants. Treatment with an a-blocker may provide a small reduction in the number of number pain episodes (MD À0.66, 95% CI: À0.91 to À0.42; P < 0.001; I² = 80%; low-quality evidence due to study limitations, inconsistency, and concerns about publication bias).
Outcome: Dose of Diclofenac
Based on 14 studies with 4 373 participants, we are uncertain whether treatment with an a-blocker reduces the use of diclofenac (MD À82.41 mg, 95% CI: À122.51 to À42.31; P < 0.001; I² = 100%; low-quality evidence due to study limitations, inconsistency, and concerns about publication bias). It was notable that the dose of diclofenac in the standard therapy group varied largely amongst studies (from 15 to 1 405 mg).
Outcome: Hospitalisation
Based on 13 studies with 1 876 participants, treatment with an a-blocker reduces the need for hospitalisation (RR 0.51, 95% CI: 0.34-0.77; P = 0.001; I² = 40%, moderate-quality evidence due to study limitations). This corresponds to 69 fewer (95% CI: 93-32 fewer) hospitalisations per 1 000 participants. Based on 19 studies with 3 292 participants, treatment with an a-blocker may have little effect on the need for surgical intervention (RR 0.74, 95% CI: 0.53-1.02; P = 0.07; I² = 37%, low-quality evidence due to study limitations and imprecision). This corresponds to 28 fewer (95% CI 51 fewer to two more) surgical interventions per 1 000 participants.
a-Blockers vs Placebo
The findings for this comparison are listed in the summary of findings table (Table 2) .
Outcome: Stone Clearance
Participants who received a-blockers were more likely to be stone-free compared to patients who received placebo (15 studies, 5 787 participants; RR 1.16, 95% CI: 1.07-1.25, P < 0.001; I² = 68%). The risk difference with a-blockers was 116 more (95% CI: 51-182 more) stone clearances per 1 000 participants. The quality of evidence was moderate due to downgrading for risk of bias and inconsistency.
Outcome: Major Adverse Events
Patients using a-blockers had more major adverse events of the medication compared to placebo drugs (10 studies, 1 650 participants; RR 2.09, 95% CI: 1.13-3.86, P = 0.02; I² = 25%).
The risk difference with a-blockers was 29 more (95% CI: 3-75 more) major adverse events per 1 000 participants. The quality of evidence was moderate due to downgrading for risk of bias and imprecision.
Outcome: Stone Expulsion Time
Stone expulsion time was shorter in patients using a-blockers compared to those receiving placebo (seven studies, 3 240 participants: MD À1.98, 95% CI: À3.71 to À0.24, P = 0.03; I² = 76%). The quality of evidence was low due to downgrading for inconsistency and imprecision.
Outcome: Pain Episodes
Number of pain episodes was not statistically different between patients using a-blockers and those receiving placebo (two studies, 215 participants: MD À0.39, 95% CI: À1.07 to 0.29, P = 0.13; I² = 57%). The quality of evidence was low due to downgrading for inconsistency and imprecision.
Outcome: Dose of Diclofenac (mg)
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Outcome: Hospitalisation
Hospitalisation was not statistically different between patients using a-blockers and those receiving placebo (two studies, 500 participants: RR 0.84, 95% CI: 0.48-1.47, P = 0.55; I² = 0%). The risk difference with a-blockers was 15 fewer (95% CI 50 fewer to 45 more) hospitalisations per 1 000 participants. The quality of evidence was moderate due to downgrading for risk of bias and imprecision.
Outcome: Surgical Intervention
Surgical intervention was not statistically different between patients using a-blockers and those receiving placebo (five studies, 1 458 participants: RR 0.93, 95% CI: 0.70-1.24, P = 0.39; I² = 1%). The risk difference with a-blockers was nine fewer (95% CI 38 fewer to 30 more) surgical interventions per 1 000 participants. The quality of evidence was high.
Subgroup Analyses
Stone Clearance
We compared the outcomes of participants with stones of ≤5 mm (14 studies, 2 622 participants) to those with stones of >5 mm (10 studies, 2 887 participants). We found RRs of 1.06 (95% CI: 0.98-1.15; P = 0.16; I² = 62%) vs 1.45 (95% CI: 1.22-1.72; P < 0.001; I² = 59%), respectively. The test for interaction was suggestive of a possible subgroup effect (v 2 = 9.96, P = 0.002; I² = 90%). Therefore, a-blockers may have little effect on stone clearance in participants with stones of ≤5 mm resulting in 48 more (95% CI 16 fewer to 121 more) stone clearances per 1 000 patients, but substantially increase stone clearance in participants with stones of >5 mm, which corresponds to 302 more (95% CI: 148-483 more) stone clearances per 1 000 participants. We rated the quality of evidence as moderate, downgrading for study limitations and imprecision.
Major Adverse Events We found no studies that reported the outcome major adverse events that permitted an analysis stratified by stone size.
Stone Location
Stone clearance In patients with distal ureteric stones, stone clearance may be improved (57 studies, 8 576 participants); RR 1.46, 95% CI: 1.36-1.57, P < 0.001; I² = 77%). The quality of evidence was low due to downgrading for risk of bias, inconsistency, and publication bias.
In patients with mid-and proximal ureteric stones, stone clearance was similar (nine studies, 794 participants); RR 1.28, 95% CI: 0.99-1.66, P = 0.06; I² = 60%). The quality of evidence was low due to downgrading for risk of bias, inconsistency, and imprecision.
Test for subgroup differences was statistically not significant (v 2 = 0.93, I² = 0%, P = 0.34). Major adverse events We found no studies that reported the outcome major adverse events that permitted an analysis stratified by stone location.
Study or Subgroup
Type of a-Blocker
Stone clearance We performed a subgroup analysis based on the type of a-blocker used, which included tamsulosin, alfuzosin, terazosin, naftopidil, and silodosin. All types of a-blockers improved stone clearance. The subgroup test for interaction was not significant (v 2 = 1.44, I² = 0%, P = 0.92).
Major adverse events
We performed a subgroup analysis based on the type of a-blocker used, which included tamsulosin, alfuzosin, doxazosin, terazosin, naftopidil, and silodosin. Major adverse events were not increased except for alfuzosin (five studies, 323 participants); RR 5.51, 95% CI: 1.46-20.83, P = 0.01; I² = 0%). However, the subgroup test for interaction was not significant (v 2 = 5.57, I² = 46.1%, P = 0.13).
Discussion
Summary of Main Results
The main findings of the present meta-analysis are that a higher stone clearance can be achieved with MET using a-blockers when compared to standard therapy without an a-blocker (low quality of evidence). The use of a-blockers does not appear to result in more major adverse events (low quality of evidence).
Based on a pre-planned sensitivity analysis based on placebocontrolled studies only, we found a-blockers to be less effective than the overall analysis of all studies; this still corresponds to a higher stone clearance but also higher major adverse events.
Based on a pre-planned subgroup analysis, we found support for a possible subgroup effect based on stone size; a-blockers may provide a clinically meaningful improvement in stone clearance in patients with stones of 6-10 mm, but not in patients with smaller stones of ≤5 mm. We did not find evidence of a subgroup effect based on stone location or type of a-blocker.
For secondary outcomes, treatment with a-blockers appears to shorten the time to stone expulsion, reduce the number of pain episodes, use of diclofenac, and need for hospitalisation, based on very low to moderate quality. Our subgroup analyses showed a possible subgroup effect for stone size based on test for interaction. The beneficial effect of a-blockers was statistically significant for stones sized 6-10 mm. For stone location and type of a-blocker, the test for subgroup differences was statistically not significant. Sensitivity analysis with only placebo-controlled trials showed a significant beneficial effect in favour of a-blockers based on a low quality of evidence. In addition, patients using a-blockers were more likely to experience major The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect; Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. Explanations: a. Downgraded due to inconsistency (high heterogeneity with an I 2 of 68%). b. Downgraded due to imprecision (wide CI consistent with negligible to substantial harm). c. Downgraded due to inconsistency (heterogeneity with an I 2 of 57%). d. Downgraded due to imprecision (wide CI; wide CI consistent with large to negligible benefit). e. Downgraded due to imprecision (wide CI consistent with no effect and small benefit). f. Downgraded due to inconsistency (high heterogeneity with an I 2 of 90%).
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Overall Completeness and Applicability of Evidence
Risk of bias was assessed with the Cochrane's Risk of bias assessment tool and the quality of evidence (see below) was determined using the GRADE approach. It should be noted that according to funnel plots asymmetry, publication bias was suspected for several outcomes, which led to downgrading the quality of the evidence.
Follow-up involved radiological examination in 50 of 67 studies (74.6%). Four studies (6.3%) did not and in 13 (20.3%) studies it was unclear whether radiological assessment was performed. We believe radiological confirmation is warranted to assess stone clearance, although reviewing images by (especially not blinded) radiologists may have introduced bias.
Because studies were conducted in a wide variety of countries worldwide, covering several continents (i.e. North America, Europe, and Asia), the results of this review are probably applicable worldwide.
Furthermore, we want to point out the potential issue of incomplete reporting of major adverse events.
Quality of the Evidence
We used GRADE to assess the quality of evidence on a per outcome basis, which frequently lowered the quality of evidence. The main issues that lowered our confidence in the estimates of effect were study limitations, specifically unclear allocation concealment, lack of blinding resulting in performance and detection bias, and potentially attrition bias.
Other issues that prompted frequent downgrading were clinical importance inconsistency in studies results, imprecision, and concerns over potential publication bias given observed funnel plot asymmetry.
Lastly, most studies did not prospectively stratify for clinically important subgroups at the time of randomisation; therefore it is unclear whether prognostic balance existed. The results of these secondary analyses therefore need to be interpreted with caution.
Potential Biases in the Review Process
We searched without any language restriction. However, there is a possibility that despite our best efforts, which included contacting the principal investigator of the existing studies, we may have missed additional studies. This may be because they were published in non-indexed journals or were unpublished.
Reporting bias was investigated using funnel plots, which showed asymmetric plots for stone clearance and major adverse events. We performed sensitivity analyses after excluding non-placebo-controlled trials and still found a favourable effect of a-blockers on stone clearance where we still suspected publication bias.
Agreements and Disagreements with Other Studies or Reviews
While many systematic reviews exist on this topic very few have been conducted with the same methodological rigor that is standard for Cochrane reviews. It is also the most up-todate, as it includes the unpublished and relatively large study that was presented by Meltzer et al. [59] at AUA 2017 and the recently published study of Ye et al. [76] .
Most of the earlier trials examining a-blocker therapy for ureteric stones conclude that there is a higher stone clearance and faster stone expulsion time. From 2013 to 2015, multiple meta-analyses were performed for different a-blockers (tamsulosin [82] , silodosin [83] , and alfuzosin [84] ) and those results were similar to those of the present review. In a metaanalysis from 2016 by Hollingsworth et al. [85] , the authors came to similar principal findings as ours, stating that a-blockers should be considered in the treatment of ureteric stones. Their meta-analysis included some multicentre placebo-controlled RCTs, which did not demonstrate a beneficial effect of a-blockers on stone clearance when compared to a placebo [41, 65, 72] . These studies were included in the present meta-analysis as well. Two of these trials involved a large percentage of small stones (75% of a-blocker patients had stones of ≤5 mm [41, 65] ). However, because these smaller stones are more likely to pass spontaneously (even without MET), this could have influenced the overall effect in these studies: i.e. the potential benefits of MET may have been diluted by the inclusion of smaller stones in these two studies. Closer analysis of the data of Furyk et al. [41] shows interestingly a favourable effect in the tamsulosin group for stones of 5-10 mm compared to placebo. The present review endorses this finding, as a significant effect of a-blockers was found in larger stones (≥6 mm) on stone clearance and possible difference in effect was indicated according to the subgroup interaction test.
The Spontaneous Urinary Stone Passage Enabled by Drugs (SUSPEND) trial by Pickard et al. [65] was designed to assess the clinical effectiveness of MET rather than therapeutic efficacy, as radiological assessment was not a primary endpoint. Although these authors concluded that MET is not effective in reducing the need for intervention at 4 weeks, the differences in stone clearance were attenuated for stones of >5 mm, favouring tamsulosin as compared to nifedipine and placebo (71.3%, 61.7% and 60.6%, respectively). Moreover, the response rate for both the 4-week questionnaire (62%) and the 12-week questionnaire (49%) was considerably lower than primary outcome participation, but could impact secondary outcome results. In the SUSPEND trial, medication adherence was not monitored, which could raise some concern. The results of the SUSPEND trial may have led to changes in clinical practice in some countries; however, this is not consistent with the findings from our present meta-analysis, which demonstrated a persistent beneficial effect of a-blockers in distal ureteric stones of >5 mm. Consistent with the SUSPEND trial, no difference was found in surgical intervention between the groups. Consistent with the findings of the SUSPEND trial, a very small proportion of participants receiving a-blockers had major adverse events, and an even smaller proportion discontinued treatment because of this.
Sur et al. [72] found a positive effect of a-blockers for distal ureteric stones based on subgroup analysis. This is consistent with the findings of the present review, i.e. that a-blockers appear most effective in the distal part of the ureter and in patients with stones of 6-10 mm.
More recently, an abstract was presented at the AUA 2017 [59] and this trial is included in our present meta-analysis. The authors also failed to demonstrate a favourable effect of a-blockers. However, stone clearance was assessed through telephone calls and as reported by patients. About 50% of the patients underwent a follow-up CT; no difference in stone clearance between groups was observed. In this trial, about 75% of the patients had stones of <5 mm; no results from any subgroup analyses based on stone size are available for this unpublished study. Apart from abnormalities of ejaculation, treatment-related adverse events did not occur more often in the a-blocker group.
The most recent published paper by Ye et al. [76] is the largest trial to date and showed a favourable effect of tamsulosin. In this double-blind, placebo-controlled study including distal ureteric stones, specific benefit of tamsulosin was shown for larger stones (>5 mm), although no results were reported regarding the test for interaction. No differences in the incidence of adverse events were identified between the two study groups. The investigators reported no serious adverse events. These findings are supported by a unique feature of this study, as patients underwent weekly non-contrast CT scans.
Conclusions
Based on both the main analysis, as well as the results of a predefined subgroup analysis of placebo-controlled studies, a-blockers improve stone clearance but may increase the risk of major adverse events slightly. In addition, several other patient-important outcomes may be improved. This information should provide valuable guidance to clinicians, patients, and guideline developers when it comes to decisionmaking about the use of a-blockers.
In clinical settings in which the stone size is known, the evidence from this review suggests that the effectiveness of a-blockers mostly relates to larger stones. This may be because the probability of smaller stones passing spontaneously is relatively high. This may have important implications for considerations of selecting an a-blocker if, e.g., the stone size has been determined accurately by a CT scan. Meanwhile, we found no indication that the indication to use an a-blocker should differ by stone location or that the effectiveness of a-blockers differs by stone type. That being said, the preponderance of evidence is with the drug tamsulosin.
Whereas the majority of trials on MET with a-blockers were of low methodological quality, prompting us to downgrade the analyses for study limitations, there is a subset of higher quality, placebo-controlled studies. Based on the present analysis, there is at least moderate quality evidence for the outcomes of stone clearance, major adverse events, hospitalisation, and surgical intervention. For these outcomes, future trials appear unlikely to change our understanding of the effects of a-blockers and may not be needed.
There is less certainty with regards to other outcomes such as patients' pain experience and need for pain medications. In addition, there remains some uncertainty as to the relative effectiveness of a-blockers depending on stone location. Future study should be placebo-controlled with adequate allocation concealment, blinding of all relevant parties (participants, personnel, and outcome assessors), and complete or near complete follow-up. In addition, it should be stratified and adequately powered for any planned secondary analyses, such as for stone size and location.
